Filing Details

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13G

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. 1)

 

EVOGENE LTD.

(Name of Issuer)

 

ORDINARY SHARES, PAR VALUE NIS 0.02 PER SHARE

(Title of Class of Securities)

 

M4119S104

(CUSIP Number)

 

October 30, 2020

(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☒

Rule 13d-1(c)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

(Continued on following page(s)

 

 

Page 1 of 5 Pages

 

 

CUSIP No. M4119S104

13G

Page 2 of 5 Pages

 

1.	NAMES OF REPORTING PERSON
	S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
	Alpha Capital Anstalt
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
	(a) ☐
	(b) ☐
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	Liechtenstein

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON	5.	SOLE VOTING POWER, – 3,132,945 Ordinary Shares (1)
	6.	SHARED VOTING POWER - None
	7.	SOLE DISPOSITIVE POWER – 3,132,945 Ordinary Shares (1)
	8.	SHARED DISPOSITIVE POWER – None

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -
	3,132,945 Ordinary Shares (1)
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
	8.81%
12.	TYPE OF REPORTING PERSON
	CO

 

(1)

Based on 35,574,954 Ordinary Shares outstanding as of October 30, 2020.

 

 

CUSIP No. M4119S104

13G

Page 3 of 5 Pages

 

ITEM 1 (a)

NAME OF ISSUER: Evogene Ltd.

 

ITEM 1 (b)

ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

 

13 Gad Feinstein Street, Park Rehovot P.O.B 2100, Rehovot 7612002, Israel

 

ITEM 2 (a)

NAME OF PERSON FILING: Alpha Capital Anstalt

 

ITEM 2 (b)

ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

 

Lettstrasse 32, FL-9490 Vaduz, Furstentums, Liechtenstein

 

ITEM 2 (c)

CITIZENSHIP: Liechtenstein

 

ITEM 2 (d)

TITLE OF CLASS OF SECURITIES: Ordinary Shares, par value NIS 0.02

 

ITEM 2 (e)

CUSIP NUMBER: M4119S104

 

ITEM 3

IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable

 

ITEM 4

OWNERSHIP

 

(a)

AMOUNT BENEFICIALLY OWNED: 3,132,945 Ordinary Shares (1)

 

(b)

PERCENT OF CLASS: 8.81%

 

(c)

NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

 

(i)

SOLE POWER TO VOTE OR DIRECT THE VOTE

 

3,132,945 Ordinary Shares (1)

 

(ii)

SHARED POWER TO VOTE OR DIRECT THE VOTE

 

0 Shares

 

(iii)

SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

 

3,132,945 Ordinary Shares (1)

 

(iv)

SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

 

0 Shares

 

 

CUSIP No. M4119S104

13G

Page 4 of 5 Pages

 

ITEM 5

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

 

Not applicable

 

ITEM 6

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

 

Not applicable

 

ITEM 7

IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

 

Not applicable

 

ITEM 8

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

 

Not applicable

 

ITEM 9

NOTICE OF DISSOLUTION OF GROUP

 

Not applicable

 

 

CUSIP No. M4119S104

13G

Page 5 of 5 Pages

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

	November 2, 2020
	(Date)
	/s/ Konrad Ackermann
	(Signature)
	Konrad Ackermann, Director
	(Name/Title)